Centogene NV
NASDAQ:CNTG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Centogene NV
Research & Development
Centogene NV
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Centogene NV
NASDAQ:CNTG
|
Research & Development
-€10.4m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Research & Development
-€2B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Research & Development
-€141.4m
|
CAGR 3-Years
44%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Research & Development
-€176.8m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Research & Development
-€56.9m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
2%
|
|
|
Formycon AG
XETRA:FYB
|
Research & Development
-€15.5m
|
CAGR 3-Years
9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Centogene NV
Glance View
Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The company is headquartered in Rostock, Mecklenburg-Vorpommern and currently employs 808 full-time employees. The company went IPO on 2019-11-07. The company focuses on transforming clinical, genetic and biochemical data into medical solutions for patients, physicians and pharmaceutical companies. The firm provides the full spectrum of methods and technology for human genetics analysis. The company develops a rare disease platform based on its real-world data repository with over 2.0 billion weighted data points from over 450,000 patients representing around 115 different, which includes epidemiologic, phenotypic and genetic data that reflects a global population, as well as a biobank of patients’ blood samples. In addition, it is active in the research and development products for human genetics. The firm operates in Germany and the United States.
See Also
What is Centogene NV's Research & Development?
Research & Development
-10.4m
EUR
Based on the financial report for Dec 31, 2023, Centogene NV's Research & Development amounts to -10.4m EUR.
What is Centogene NV's Research & Development growth rate?
Research & Development CAGR 5Y
-11%
Over the last year, the Research & Development growth was 29%. The average annual Research & Development growth rates for Centogene NV have been 11% over the past three years , -11% over the past five years .
